Eicosanoids in metabolic syndrome.

Title

Eicosanoids in metabolic syndrome.

Creator

Hardwick James P; Eckman Katie; Lee Yoon-Kwang; Abdelmegeed Mohamed A; Esterle Andrew; Chilian William M; Chiang John Y; Song Byoung-Joon

Publisher

Advances in pharmacology (San Diego, Calif.)

Date

2013
1905-7

Description

Chronic persistent inflammation plays a significant role in disease pathology of cancer, cardiovascular disease, and metabolic syndrome (MetS). MetS is a constellation of diseases that include obesity, diabetes, hypertension, dyslipidemia, hypertriglyceridemia, and hypercholesterolemia. Nonalcoholic fatty liver disease (NAFLD) is associated with many of the MetS diseases. These metabolic derangements trigger a persistent inflammatory cascade, which includes production of lipid autacoids (eicosanoids) that recruit immune cells to the site of injury and subsequent expression of cytokines and chemokines that amplify the inflammatory response. In acute inflammation, the transcellular synthesis of antiinflammatory eicosanoids resolve inflammation, while persistent activation of the autacoid-cytokine-chemokine cascade in metabolic disease leads to chronic inflammation and accompanying tissue pathology. Many drugs targeting the eicosanoid pathways have been shown to be effective in the treatment of MetS, suggesting a common linkage between inflammation, MetS and drug metabolism. The cross-talk between inflammation and MetS seems apparent because of the growing evidence linking immune cell activation and metabolic disorders such as insulin resistance, dyslipidemia, and hypertriglyceridemia. Thus modulation of lipid metabolism through either dietary adjustment or selective drugs may become a new paradigm in the treatment of metabolic disorders. This review focuses on the mechanisms linking eicosanoid metabolism to persistent inflammation and altered lipid and carbohydrate metabolism in MetS.

Subject

Adipose Tissue; Animals; Eicosanoids/*metabolism; Fatty Liver/etiology/immunology/metabolism; Humans; Immune System/immunology/metabolism; Lipid Metabolism; Metabolic Syndrome/complications/immunology/*metabolism/physiopathology; Non-alcoholic Fatty Liver Disease; Obesity/complications/immunology/metabolism; Sepsis/complications/immunology/metabolism; White/immunology/metabolism

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

157–266

Volume

66

Citation

Hardwick James P; Eckman Katie; Lee Yoon-Kwang; Abdelmegeed Mohamed A; Esterle Andrew; Chilian William M; Chiang John Y; Song Byoung-Joon, “Eicosanoids in metabolic syndrome.,” NEOMED Bibliography Database, accessed January 16, 2022, https://neomed.omeka.net/items/show/3394.

Social Bookmarking